FDA advisory panels vote down two cancer drugs...FDA advisors voted 16-1 against Allos Therapeutics’ (ALTH) drug RSR13 designed to make radiation treatment more effective by increasing oxygen delivery in the tumor. The trial was conducted in breast cancer patients. The FDA still has to decide on whether to approve the product, but the agency tends to follow the recommendations of its panels. Trading was halted Monday afternoon while the panel considered the drug. Allos had already lost 6.3% earlier Monday, after losing 45% on Friday on word that FDA staff reviewers found the drug to be unconvincing.
